ACTRN12621001234808招募中未知
Emerging Drugs Network of Australia: a national multi-centre prospective toxicosurveillance system of illicit and emerging drugs detected in emergency department presentations
Harry Perkins Institute of Medical Research0 个研究点目标入组 5,000 人开始时间: 2021年9月13日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 5,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 16 Years 至 o limit（—）
- 性别
- All
入选标准
- •Inclusion Criteria:
- •Clinical features of severe illicit drug intoxication include:
- •1. Stimulant toxicity (sympathomimetic, serotonergic or anticholinergic toxicity)
- •- Patients requiring intravenous sedation for manifestations of toxicity;
- •- Patients with illness critical enough to require ICU level care.
- •2. Hallucinogenic toxicity
- •- Patients requiring intravenous sedation for manifestations of toxicity;
- •- Patients with illness critical enough to require ICU level care.
- •3. Opioid toxicity
- •- Patients requiring a large initial dose of naloxone (e.g. >400microgram in first hour);
- •- Patients requiring multiple repeat doses or an infusion of naloxone;
- •- Patients with illness critical enough to require ICU level care.
- •Additional suggestive features of drug toxicity will be sought to determine eligibility, including reports of recreational drug use by the patient or collaterals (i.e. family, friends, witnesses, police, ambulance), presentation from a public event (e.g. festival or concert) and/or multiple patients from the same location presenting with similar clinical features.
排除标准
- •1. Patients with clinically mild drug toxicity, or where intravenous access is not required;
- •2. Patients presenting with agitation that is considered by the clinician to be predominantly related to methamphetamine-induced psychosis, without significant physiologic manifestations suggestive of acute drug intoxication;
- •3. Patients under the age of 16 years.
研究者
相似试验
进行中（未招募）
1 期
A mulitnational, multicenter, exploratory pharmacogenomics trial to test the importance of identified genetic markers, and potentially identify new markers of various ovarian responses to GONAL-f® treatment in women undergoing assisted reproduction technology (ART).Ensayo exploratorio farmacogenómico, multinacional y multicéntrico, para examinar la importancia de los marcadores genéticos identificados y, potencialmente, identificar nuevos marcadores de diversas respuestas ováricas al tratamiento con GONAL f® en mujeres sometidas a técnicas de reproducción asistida (ART) - Pharmacogenomics trial of GONAL-f® in ARTFemales undergoing assisted reproductive technology (ART), in vitro fertilisation (IVF) or intra cytoplasmic sperm injection (ICSI)Mujeres sometidas a ténicas de reproducción asistida (ART), fertilización in vitro (IVF) o inyección intracitoplásmica de espermatozoides (ICSI)MedDRA version: 9.1Level: LLTClassification code 10021930Term: Infertility NOSEUCTR2008-001174-33-ESMerck Serono International, A branch of Laboratoires Serono S.A.
进行中（未招募）
不适用
A mulitnational, multicenter, exploratory pharmacogenomics trial to test the importance of identified genetic markers, and potentially identify new markers of various ovarian responses to GONAL-f® treatment in women undergoing assisted reproduction technology (ART). - Pharmacogenomics trial of GONAL-f® in ARTFemales undergoing assisted reproductive technology (ART), in vitro fertilisation (IVF) or intra cytoplasmic sperm injection (ICSI)MedDRA version: 9.1Level: LLTClassification code 10021930Term: Infertility NOSEUCTR2008-001174-33-SEMerck Serono International S.A., A branch of Laboratoires Serono S.A.1,500
进行中（未招募）
不适用
A multinational, multicenter, exploratory pharmacogenomics trial to test the importance of identified genetic markers, and potentially identify new markers of various ovarian responses to GONAL-f® treatment in women undergoing assisted reproduction technology (ART). - Pharmacogenomics trial of GONAL-f® in ARTFemales undergoing assisted reproductive technology (ART), in vitro fertilisation (IVF) or intra cytoplasmic sperm injection (ICSI)MedDRA version: 9.1Level: LLTClassification code 10021930Term: Infertility NOSEUCTR2008-001174-33-ATMerck Serono International, A branch of Laboratoires Serono S.A.1,500
进行中（未招募）
不适用
A multinational, multicenter, exploratory pharmacogenomics trial to test the importance of identified genetic markers, and potentially identify new markers of various ovarian responses to GONAL-f® treatment in women undergoing assisted reproduction technology (ART). - Pharmacogenomics trial of GONAL-f® in ARTEUCTR2008-001174-33-GBMerck Serono International, A branch of Laboratoires Serono S.A.1,500
进行中（未招募）
1 期
A multinational, multicenter, exploratory pharmacogenomics trial to test the importance of identified genetic markers, and potentially identify new markers of various ovarian responses to GONAL-f® treatment in women undergoing assisted reproduction technology (ART). - Pharmacogenomics trial of GONAL-f® in ARTEUCTR2008-001174-33-FRMerck Serono International, A branch of Laboratoires Serono S.A.